Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy

Affiliations

¹ St. Vincent's Hospital, University of Melbourne, Melbourne, Victoria, Australia.
² Winship Cancer Institute, Emory University, Atlanta, GA, USA.
³ Nizhniy Novgorod Region Clinical Hospital, Nizniy Novgorod, Russia.
⁴ Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada.
⁵ Samsung Medical Center, Sungkyunkwan University, Seoul, Korea.
⁶ Hôpital Claude Huriez, Lille, France.
⁷ Alfred Health-Monash University, Melbourne, Australia.
⁸ Atrium Health, Charlotte, NC, USA.
⁹ Silesian Medical University, Katowice, Poland.
¹⁰ Japanese Red Cross Medical Center, Tokyo, Japan.
¹¹ General Hospital Evangelismos, Athens, Greece.
¹² University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
¹³ Amgen, Inc., Thousand Oaks, CA, USA.
¹⁴ University Hospital Salamanca/IBSAL, Salamanca, Spain.

Clinical Trial

Hang Quach et al. Br J Haematol. 2021 Aug.

. 2021 Aug;194(4):784-788.

doi: 10.1111/bjh.17541. Epub 2021 May 28.

¹ St. Vincent's Hospital, University of Melbourne, Melbourne, Victoria, Australia.
² Winship Cancer Institute, Emory University, Atlanta, GA, USA.
³ Nizhniy Novgorod Region Clinical Hospital, Nizniy Novgorod, Russia.
⁴ Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada.
⁵ Samsung Medical Center, Sungkyunkwan University, Seoul, Korea.
⁶ Hôpital Claude Huriez, Lille, France.
⁷ Alfred Health-Monash University, Melbourne, Australia.
⁸ Atrium Health, Charlotte, NC, USA.
⁹ Silesian Medical University, Katowice, Poland.
¹⁰ Japanese Red Cross Medical Center, Tokyo, Japan.
¹¹ General Hospital Evangelismos, Athens, Greece.
¹² University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
¹³ Amgen, Inc., Thousand Oaks, CA, USA.
¹⁴ University Hospital Salamanca/IBSAL, Salamanca, Spain.

No abstract available

Keywords: cancer; clinical studies; clinical trials; multiple myeloma.

References

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Chronic Myeloid Leukemia Version 3.2020. Fort Washington, PA: National Comprehensive Cancer Network; 2020.
1. Moreau P, Zamagni E, Mateos MV. Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide. Blood Cancer J. 2019;9:38.
1. Migkou M, Gavriatopoulou M, Terpos E, Dimopoulos MA. Optimizing therapy in bortezomib-exposed patients with multiple myeloma. Expert Rev Hematol. 2018;11:463-9.
1. Harousseau JL, Attal M. How I treat first relapse of myeloma. Blood. 2017;130:963-73.
1. KYPROLIS® (carfilzomib) [package insert]. Thousand Oaks, CA: Amgen, Inc.; 2020.